Healthcare
Orion Oyj(ORINY)
Live Price
Offline$39.00
+0.00% today
1Y Change
+4.77%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $9.67B
- Revenue Growth
- +22.5%
- EPS Growth
- -27.2%
- Dividend Yield
- 2.5%
Coverage: 255 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Orion Oyj (ORINY) is a Healthcare stock with a market cap of $9.67B and listed on OTC. The stock last traded around $39.00 and up 4.8% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +22.5%, EPS growth of -27.2%, a dividend yield of 2.5%. What stands out right now is revenue +22.5%, EPS -27.2%, free cash flow +6.2% with operating margin 34.1% and ROIC 35.4%. The dividend matters to the case here, with a current yield around 2.5%. Valuation sits in the middle of the pack at P/E 18.3 and price/sales 5.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines ORINY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+22.5% vs +7.6% peer median
Operating Margin
Above sector median
+34.1% vs +19.4% peer median
P/E
Below sector median
18.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Feb 4, 2026 with revenue ahead of estimates by +15.6%.
The operating picture looks softer than before
Revenue is at +22.5% and EPS is at -27.2%, with operating margin around 34.1%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 4, 2026 | โ | +0.0% | +0.0% | -7.1% |
2025 Oct 28, 2025 | โ | +0.0% | -13.6% | -16.1% |
2025 Jul 18, 2025 | โ | +0.0% | +6.8% | -1.1% |
Benchmark Edge
ORINY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORINY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORINY Max Drawdown
-25.57%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ORINY and SPY.
Company Overview
Orion Oyj
Other OTC
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
- Leadership
- Liisa Hurme
- IPO Date
- Dec 9, 2014
- Employees
- 3.9k
- Street Address
- Orionintie 1A
- Mailing
- Espoo, 02200
- Region
- Espoo, FI
- Reporting Currency
- USD
- Investor Line
- 358 10 4261
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.3
- EV/EBITDA
- 14.1
- Price/Sales
- 5.0
- Price/Book
- 8.6
Growth
- Revenue
- +22.5%
- EPS
- -27.2%
- Free Cash Flow
- +6.2%
Profitability
- Gross Margin
- 64.8%
- Operating Margin
- 34.1%
- Net Margin
- 27.1%
- ROE
- 48.7%
- ROIC
- 35.4%
Balance Sheet
- Debt/Equity
- 0.29
- Current Ratio
- 1.77
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.